Free Trial

Integra LifeSciences (IART) Stock Forecast & Price Target

Integra LifeSciences logo
$23.70 -0.54 (-2.23%)
(As of 11/26/2024 ET)

Integra LifeSciences - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
3
Hold
4
Buy
1

Based on 8 Wall Street analysts who have issued ratings for Integra LifeSciences in the last 12 months, the stock has a consensus rating of "Reduce." Out of the 8 analysts, 3 have given a sell rating, 4 have given a hold rating, and 1 has given a buy rating for IART.

Consensus Price Target

$24.00
1.27% Upside
According to the 8 analysts' twelve-month price targets for Integra LifeSciences, the average price target is $24.00. The highest price target for IART is $35.00, while the lowest price target for IART is $18.00. The average price target represents a forecasted upside of 1.27% from the current price of $23.70.
Get the Latest News and Ratings for IART and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Integra LifeSciences and its competitors.

Sign Up

IART Analyst Ratings Over Time

TypeCurrent Forecast
11/27/23 to 11/26/24
1 Month Ago
10/28/23 to 10/27/24
3 Months Ago
8/29/23 to 8/28/24
1 Year Ago
11/27/22 to 11/27/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
1 Buy rating(s)
2 Buy rating(s)
2 Buy rating(s)
3 Buy rating(s)
Hold
4 Hold rating(s)
4 Hold rating(s)
3 Hold rating(s)
2 Hold rating(s)
Sell
3 Sell rating(s)
3 Sell rating(s)
4 Sell rating(s)
3 Sell rating(s)
Consensus Price Target$24.00$26.50$28.63$45.63
Forecasted Upside1.27% Upside39.84% Upside40.66% Upside17.96% Upside
Consensus Rating
Reduce
Reduce
Reduce
Hold

IART Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

IART Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Integra LifeSciences Stock vs. The Competition

TypeIntegra LifeSciencesMedical CompaniesS&P 500
Consensus Rating Score
1.75
2.80
2.50
Consensus RatingReduceModerate BuyModerate Buy
Predicted Upside1.10% Upside25,411.29% Upside7.11% Upside
News Sentiment Rating
Positive News

See Recent IART News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/5/2024Citigroup
3 of 5 stars
J. Wuensch
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetSell ➝ Sell$16.00 ➝ $22.00-9.84%
10/14/2024Truist Financial
2 of 5 stars
 Lower TargetHold ➝ Hold$26.00 ➝ $21.00+10.64%
10/7/2024Bank of America
4 of 5 stars
 Lower TargetUnderperform ➝ Underperform$26.00 ➝ $18.00+4.23%
10/7/2024BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
R. Zimmerman
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeSell ➝ Neutral
7/30/2024JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetMarket Outperform ➝ Market Outperform$40.00 ➝ $35.00+37.09%
7/15/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetUnderweight ➝ Underweight$24.00 ➝ $27.00-9.12%
DeFi Coin on Verge of Breakout! (Ad)

The blueprint for millionaires is here. Don't let this be the missed opportunity you regret for years.

Claim your FREE book now before it's too late!
5/7/2024Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Market Perform
5/7/2024Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOverweight ➝ Equal Weight$45.00 ➝ $25.00+8.04%
11/14/2023CL King
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$50.00+36.61%
7/12/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy$58.00 ➝ $53.00+28.33%
6/26/2023Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$55.00 ➝ $44.00+11.25%
6/8/2023Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold
5/24/2023JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeNeutral ➝ Underweight$56.00 ➝ $43.00+6.23%
5/23/202322nd Century Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingDowngrade

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 05:27 PM ET.


IART Forecast - Frequently Asked Questions

According to the research reports of 8 Wall Street equities research analysts, the average twelve-month stock price forecast for Integra LifeSciences is $24.00, with a high forecast of $35.00 and a low forecast of $18.00.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Integra LifeSciences in the last twelve months. There are currently 3 sell ratings, 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "reduce" IART shares.

According to analysts, Integra LifeSciences's stock has a predicted upside of 1.27% based on their 12-month stock forecasts.

Over the previous 90 days, Integra LifeSciences's stock had 1 upgrade by analysts.

Integra LifeSciences has been rated by research analysts at Bank of America, BTIG Research, Citigroup, and Truist Financial in the past 90 days.

Analysts like Integra LifeSciences less than other "medical" companies. The consensus rating for Integra LifeSciences is Reduce while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how IART compares to other companies.


This page (NASDAQ:IART) was last updated on 11/26/2024 by MarketBeat.com Staff
From Our Partners